Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 多克隆抗體
  4. AGPAT2 Antibody

AGPAT2 Antibody

  • 中文名稱：
    AGPAT2兔多克隆抗體
  • 貨號：
    CSB-PA101475
  • 規(guī)格：
    ￥1100
  • 圖片：
    • Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human fetal liver cancer tissue, Primary antibody: CSB-PA101475(AGPAT2 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds
  • 其他：

產(chǎn)品詳情

  • Uniprot No.：
  • 基因名：
  • 別名：
    AGPAT2; 1-acyl-sn-glycerol-3-phosphate acyltransferase beta; 1-acylglycerol-3-phosphate O-acyltransferase 2; 1-AGP acyltransferase 2; 1-AGPAT 2; Lysophosphatidic acid acyltransferase beta; LPAAT-beta
  • 宿主：
    Rabbit
  • 反應種屬：
    Human
  • 免疫原：
    Synthetic peptide of Human AGPAT2
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標記方式：
    Non-conjugated
  • 抗體亞型：
    IgG
  • 純化方式：
    Antigen affinity purification
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
  • 產(chǎn)品提供形式：
    Liquid
  • 應用范圍：
    ELISA,WB
  • 推薦稀釋比：
    Application Recommended Dilution
    ELISA 1:2000-1:5000
    WB 1:500-1:2000
  • Protocols：
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

產(chǎn)品評價

靶點詳情

  • 功能：
    Converts 1-acyl-sn-glycerol-3-phosphate (lysophosphatidic acid or LPA) into 1,2-diacyl-sn-glycerol-3-phosphate (phosphatidic acid or PA) by incorporating an acyl moiety at the sn-2 position of the glycerol backbone.
  • 基因功能參考文獻：
    1. The findings demonstrate that AGPAT2, which is mutated in patients with congenital generalized lipodystrophy and over-expressed in different types of cancer, is a direct transcriptional target of HIF-1, suggesting that upregulation of lipid storage by HIF-1 plays an important role in adaptation and survival of cancer cells under low oxygen conditions. PMID: 29908837
    2. Results show that LPAATbeta had high expression in osteosarcoma patients who received cisplatin treatment and cisplatin-resistant cancer cell lines. In vitro and in vivo studies provide evidence that LPAATB plays an important role in osteosarcoma. PMID: 28035350
    3. Data show that missense mutation c.299G>A changes serine in the acyltransferase NHX4D motif of AGPAT2, and intronic c.493-1G>C mutation destroy a splicing site that leads to exon 4 skipping and deletion of whole AGPAT2 substrate binding domain. PMID: 24498038
    4. the ability of LPAAT-beta to regulate mTOR function PMID: 24205284
    5. miR-24 may play an important role in inhibiting osteosarcoma growth through suppression of LPAATbeta. PMID: 23578572
    6. novel nonsense a missense mutations were found in two patients with congenital generalized lipodystrophy type 1. PMID: 22902344
    7. Data suggest that AGPAT2 regulates adipogenesis through modulation of lipid metabolism/signal transduction, altering normal activation of phosphatidylinositol 3-kinase (PI3K)/protooncogene c-Akt and PPARgamma signaling in early stage of adipogenesis. PMID: 22872237
    8. the role of AGPAT1 or AGPAT2 in liver lipogenesis is minimal and that accumulation of liver fat is primarily a consequence of insulin resistance PMID: 21873652
    9. lpaat beta gene overexpression exists in both AML and CML patients. lpaat beta produced by AML cells probably plays an important role in abnormal proliferation and drug-resistance of AML cells. PMID: 21176343
    10. Lysophosphatidic acid acyltransferase beta (LPAATbeta) promotes the tumor growth of human osteosarcoma PMID: 21152068
    11. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. PMID: 11967537
    12. Congenital lipodystrophy patients with Seipin mutations have a more severe lack of body fat, which affects both metabolically active and mechanical adipose tissue, compared with patients with mutations in the AGPAT2 gene. PMID: 14602785
    13. mutations in AGPAT2 and Gng3lg are approximately equally represented in congenital generalized lipodystrophy PMID: 15181077
    14. reduction in AGPAT2 enzymatic activity underlies the loss of adipose tissue in congenital generalized lipodystrophy PMID: 15629135
    15. Our study shows that LPAAT-beta is upregulated in ovarian cancer and is more prevalent in poorly differentiated tumours PMID: 15841084
    16. mutations in AGPAT2 or Seipin may have roles in Berardinelli-Seip congenital lipodystrophy PMID: 16435205
    17. Berardinelli-Seip syndrome is a congenital form of generalized lipodystrophy, transmitted as an autosomal recessive trait. It is well documented in medicine and skin. It is a rare disorder caused by mutations of AGPAT2 gene or BSCL2 gene. PMID: 18155601
    18. A new subtype of congenital generalized lipodystrophy is not associated with the AGPAT2 gene. PMID: 18698612
    19. We have demonstrated four novel mutations of the BSCL2 and AGPAT2 genes responsible for Berardinelli-Seip syndrome and Brunzell syndrome (AGPAT2-related syndrome). PMID: 19226263
    20. Study showed that the cellular level of lysophosphatidic acid was increased in AGPAT2 deficient cells. PMID: 19278620

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Congenital generalized lipodystrophy 1 (CGL1)
  • 亞細胞定位：
    Endoplasmic reticulum membrane; Multi-pass membrane protein.
  • 蛋白家族：
    1-acyl-sn-glycerol-3-phosphate acyltransferase family
  • 組織特異性：
    Expressed predominantly in adipose tissue, pancreas and liver.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 325

    OMIM: 603100

    KEGG: hsa:10555

    STRING: 9606.ENSP00000360761

    UniGene: Hs.320151